Photodynamic Therapy for Inflammatory CNV: Do We Know Enough?

REFERENCES

• Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP Report 2. Arch Ophthalmol. 2001; 119: 198–207, [CSA]
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol. 2001; 131: 541–560, [CSA]
   PubMed Web of Science ®Google Scholar
• Verteporfin In Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP Report No. 3. Ophthalmology. 2003; 110: 667–673, [CSA]
   PubMed Web of Science ®Google Scholar
• Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin In Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration—TAP and VIP Report No. 1. Am J Ophthalmol. 2003; 136: 407–418, [CSA]
   Google Scholar
• Rogers A H, Duker S J, Nichols N, Baker B J. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology. 2003; 110: 1315–1320, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Wachtlin J, Heimann H, Behme T, Foerster M H. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe's Arch Clin Exp Ophthalmol 2003; 241: 899–906, [CSA]
   PubMed Web of Science ®Google Scholar
• Leslie T, Lois N, Christopoulou D, Olson J A, Forrester J V. Photodynamic therapy for inflammatory choroidal neovascularization unresponsive to immunosuppression. Br J Ophthalmol. 2005; 89: 147–150, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Dunlop A AS, Cree I A, Hague S, Luthert P J, Lightman S. Multifocal Choroiditis: Clinicopathologic Correlation. Arch Ophthalmol. 1998; 116: 801–803, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Flaxel C J, Owens S L, Mulholland B, Schwartz S D, Gregor Z J. The use of corticosteriods for choroidal neovascularization in young patients. Eye. 1998; 12: 266–272, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dees C, Arnold J J, Forrester J V, Dick A D. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998; 116: 1456–1461, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Rogers A H, Martidis A, Greenberg P B, Puliafito C A. Optical Coherence Tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2002; 134: 566–576, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Treatment of Age-related Macular Degeneration With Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol. 1999; 117: 1329–1345, [CSA]
   PubMed Web of Science ®Google Scholar
• Schlingemann R O. Role of growth factors and the wound healing response in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol. 2004; 242: 91–101, [CSA]
   PubMed Web of Science ®Google Scholar
• Grossniklaus H E, Ling J X, Wallace T M, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Molecular Vision. 2002; 8: 119–26, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Reddy V M, Zamora R L, Kaplan H J. Distribution of growth factors in subfoveal neovascular membranes in age-related macular degeneration and presumed ocular histoplasmosis syndrome. Am J Ophthalmol. 1995; 120: 291–301, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ciulla T A, Walker J D, Fong D S, Criswell M H. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004; 15: 211–220, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Spaide R F, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005; 112: 301–4, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gragoudas E S, Adamis A P, Cunningham E T, Feinsod M, Guyer D R. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351: 2805–2816, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld P J. Treatment of neovascular age-related macular degeneration with Rantizunab/Lucentis. Klin Monatsbl Augenheilkd. 2005; 222: 480–484, [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar